Navigation Links
ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
Date:9/27/2007

sorbate 80 or other detergents and is intended to reduce the severity and/or incidence of hypersensitivity reactions. Docetaxel is an anti-cancer agent that acts by disrupting the cellular microtubular network that is essential for cell division. Immunosuppressant premedication is recommended for docetaxel therapy to reduce the incidence and severity of hypersensitivity reactions. Docetaxel is approved to treat breast, non-small cell lung, prostate, gastric and head and neck cancers. In connection with a Section 505(b)(2) NDA covering ANX-514, ADVENTRX must certify that all applicable docetaxel patents have expired prior to the manufacture, use or sale of ANX-514.

About Section 505(b)(2)

Section 505(b)(2) of the U.S. Food, Drug & Cosmetic Act (FDCA) allows the FDA to approve a follow-on drug on the basis of data in the scientific literature or conclusions regarding safety or effectiveness made by the FDA in the approval of other drugs. This regulatory pathway potentially makes it easier for drug manufacturers to obtain rapid approval of new forms of drugs based on the FDA's approval of the original drug. Some examples of products that may be allowed to follow a 505(b)(2) path to approval are drugs that have a new dosage form, strength, route of administration, formulation or indication. Upon approval, a drug may be marketed only for the FDA-approved indications in the approved dosage forms. Further clinical trials are necessary to gain approval for the use of the product for any additional indications or dosage forms.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases. The Company seeks to improve the performance and safety of existing treatments by addressing significant problems such as drug metabolism, bioavailability, excessive toxicity and treatment resistance. More inf
'/>"/>

SOURCE ADVENTRX Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2009)... Dec. 10 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE ... sciences product development company that identifies and advances ... various stages of development, today provided an update ... the merger of Cytopia Ltd. into YM, details ... The board of directors of Cytopia has unanimously ...
(Date:12/10/2009)... Iowa, Dec. 10 Vivakor, Inc. ... it has entered into an exclusive, $5 ... Regeneca International, Inc. ( www.regeneca.com ). ... rights to a new cutting-edge nutraceutical formulation ... development of future formulations by Vivakor for ...
(Date:12/10/2009)... (NASDAQ: MATK) announced today that it has entered into ... Fonterra Co-operative Group Limited for the use of Martek’s products ... pregnant and nursing mothers. , ... ... Corporation (NASDAQ: MATK) announced today that it has entered ...
(Date:12/10/2009)... Dec. 10 Northwest Biotherapeutics, Inc. ("NWBT" or ... Robert A. Farmer has joined the company,s Board of ... and Harvard Law School, currently serves on six other ... the national treasurer of four presidential campaigns, including those ... Glenn. In those roles, he led fundraising of ...
Breaking Biology Technology:YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 2YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 3YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 4Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 2Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 3Martek Signs Sole-Source Supply Agreement with Fonterra 2Martek Signs Sole-Source Supply Agreement with Fonterra 3Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors 2Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors 3
... March 13 Covance Inc. (NYSE: ... its clinical pharmacology footprint in Europe with the ... research company based in Basel, Switzerland."Our clients, need ... help them make decisions faster is growing," said ...
... 13 Varian Medical Systems (NYSE: VAR ) ... non-destructive testing market at the upcoming ASNT Research Symposium and ... Hotel in St. Louis, MO.The company will exhibit a number ... , A ...
... Some of the world,s most respected energy experts will be exploring ... the Energy Capital of the World, as the Greater Houston Partnership ... policy by hosting "America,s Energy Future: Assessing Our Paths to Energy ... ...
Other Biology Technology:Covance Increases Early Clinical Footprint in Europe with Acquisition of Swiss-Based Early Clinical Development Site 2Varian Medical Systems to Exhibit X-ray and CT Technologies for Non-Destructive Testing at the Upcoming ASNT 18th Annual Spring Conference 2Greater Houston Partnership to Lead Energy Security Discussion 2
(Date:12/14/2009)... HOUSTON -- (Dec. 14, 2009) -- Researchers at Rice ... a single nanoparticle that can be tracked in real ... cells, tags them with a fluorescent dye and kills ... the first examples from a growing field called "theranostics" ... treat diseases in a single procedure. , The research ...
(Date:12/14/2009)... and the Biomedical Engineering Society (BMES) have founded a ... CVET ). CVET is a forum ... medical treatment. The first issue of the new ... two other BMES publications at Springer, Annals of ... . , Cardiovascular Engineering and Technology will ...
(Date:12/14/2009)... once thought of tool use as a defining feature of ... other primates, along with birds and an array of other ... Current Biology , a Cell Press publication, adds an ... veined octopus under study manages a behavioral trick that the ... itself over stacked, upright coconut shell "bowls," makes its eight ...
Breaking Biology News(10 mins):Tracking new cancer-killing particles with MRI 2Biomedical Engineering Society's new journal to be published by Springer 2Tool use in an invertebrate: The coconut-carrying octopus 2Swine Flu Infection Rates Continue to Fall 63147 1Swine Flu Infection Rates Continue to Fall 63147 2Swine Flu Infection Rates Continue to Fall 63147 3Abbott Declares 344th Consecutive Quarterly Dividend 63144 1Childrens Hospital Surgeon Receives Prestigious Paul Tessier Medal 63141 1Childrens Hospital Surgeon Receives Prestigious Paul Tessier Medal 63141 2
... years of near-zero growth in atmospheric methane concentrations, levels ... good news for future global warming," says CSIRO,s Dr ... in Geophysical Research Letters, a journal of the American ... important greenhouse gases, namely methane and the CFCs, had ...
... L-1 to Open 75+ Centers and Expects to Process ... Requiring,Fingerprint-based Background Checks, STAMFORD, Conn., Oct. 29 ... provider of identity solutions and,services, was selected by the ... a,five-year contract estimated at up to $250 million to ...
... Whether it,s in the human body or under the ... Physicians and geologists will be meeting at the University of ... , Through a partnership between UH, M.D. Anderson ... seismic imaging will gather to explore the potential for cross-collaboration ...
Other Biology News:Global methane levels on the rise again 2L-1 Identity Solutions Selected by the State of New York as the Winning Bidder to Provide Enrollment Services for a Contract Estimated at Up to $250 Million 2L-1 Identity Solutions Selected by the State of New York as the Winning Bidder to Provide Enrollment Services for a Contract Estimated at Up to $250 Million 3L-1 Identity Solutions Selected by the State of New York as the Winning Bidder to Provide Enrollment Services for a Contract Estimated at Up to $250 Million 4Similarities in imaging the human body, Earth's crust focus of conference at UH 2
...
Rabbit polyclonal to LCAT ( Abpromise for all tested applications). entrezGeneID: 3931 SwissProtID: P04180...
HAMP Immunogen: HAMP (AAH20612, 25 a.a. ~ 85 a.a) full length recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
... Nabeta2. The epitope specific for ... any other known proteins.,SPECIES REACTIVITIES: ... work on human because the ... (17/19 residues). Reactivity with other ...
Biology Products: